Industry
Biotechnology
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
December 12, 2023 | 5:31 pm
Portfolio Pulse from Benzinga Insights
December 07, 2023 | 1:07 pm
Portfolio Pulse from Benzinga Insights
December 06, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Insights
December 01, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 06, 2023 | 11:40 am
Portfolio Pulse from Benzinga Insights
May 19, 2023 | 5:59 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.